BioSpace News Archive

Oncoinvent AS announced the presentation of preliminary 18-month safety and efficacy data from its ongoing Phase 1/2A clinical trial evaluating the safety, tolerability, and signal of efficacy of Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer at the 13th International Congress on Peritoneal Surface Malignancies of the Peritoneal Surface Oncology Group International, to be held at the Palazzo del Cinema in Venice, Italy from October 4 - 6, 2023.

ViroCell Biologics, a specialist contract development and manufacturing organisation in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President of Business Development and Makis Sigalas as Senior Business Development Director.

EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London.

DiFusion Technologies, an industry leader in advanced biomaterials for surgical implants, announced today the results of a recent case series noting the benefits of the company’s proprietary ZFUZE™ technology.

Nuvig Therapeutics, Inc., a private biotech company developing novel biologic therapeutics to treat inflammatory autoimmune diseases, announced today the appointment of Alan Glicklich, M.D., as Chief Medical Officer.

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) nonprescription pathways, announces completion of a pivotal label comprehension study (LCS).

Biome Analytics, a leading innovator in cardiovascular performance improvement, is excited to announce the immediate availability of the Biome Surveillance Manager™, its advanced Cardiac Ultrasound Management tool.

Paragonix Technologies, a pioneer in organ transplant solutions, is excited to announce the opening of its new corporate headquarters in Waltham, Massachusetts, marking a significant milestone in its journey to advance organ transplant innovations.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Frontiers in Oncology demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, to detect progression early, with high sensitivity and specificity, and risk stratify patients with unresectable stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiotherapy.

Today, the U.S. Food and Drug Administration published a new draft guidance to assist sponsors in developing treatments for stimulant use disorders.